Document Classification

Section Type: RESULTS

Text: All three efficacy end points met the prespecified noninferiority margin of 10 percentage points for oritavancin versus vancomycin : primary end point, 82. 3 % versus 78. 9 % (95 % confidence interval [CI] for the difference, -1. 6 to 8. 4 percentage points) ; investigator-assessed clinical cure, 79. 6 % versus 80. 0 % (95 % CI for the difference, -5. 5 to 4. 7 percentage points) ; and proportion of patients with a reduction in lesion area of 20 % or more, 86. 9 % versus 82. 9 % (95 % CI for the difference, -0. 5 to 8. 6 percentage points).